Lab
Elite Medical Laboratory Solutions LLC
Elite Medical Laboratory Solutions LLC was paid $1.03M by Medicaid between May 2018 and Apr 2023, across 103 billing codes. Its largest line is 81408, — 22% of everything it billed.
33Billing provider infoELITE MEDICAL LABORATORY SOLUTIONS LLC
TOMBALL, TX 77375
TOMBALL, TX 77375
33aNPI1366820870assigned 05/16/2015
33bProvider typeClinical Medical Laboratory
28Total paid$1.03M
24GClaims58,404
24DCodes billed103
24AFirst – last monthMay 2018 – Apr 2023
Compared with peers
Next to other Clinical Medical Laboratory providers in Texas
Rank by total paid#67 of 436
Median peer was paid$17K
This provider vs. median60×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 81 | $0.00 | |
| 2020 | 13,259 | $150K | |
| 2021 | 27,768 | $523K | |
| 2022 | 11,933 | $278K | |
| 2023 | 5,363 | $82K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 81408 | 22% | 3,185 | 1,436 | $222K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 21% | 7,726 | 3,141 | $213K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 9.4% | 4,373 | 2,617 | $97K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 9.2% | 2,669 | 1,879 | $95K |
| 0051U | 4.6% | 707 | 435 | $47K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.9% | 4,465 | 2,556 | $40K |
| 81162 | 3.1% | 27 | 26 | $32K | |
| 81407 | 3.1% | 1,382 | 1,150 | $32K | |
| 81405 | 2.4% | 2,974 | 1,338 | $25K | |
| 86003 | 2.4% | 617 | 552 | $24K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 2.3% | 2,740 | 1,242 | $24K |
| 81406 | 2.2% | 2,972 | 1,338 | $23K |
91 more codes
| 81404 | 2.1% | 2,874 | $22K | |
| 81403 | 1.4% | 2,580 | $15K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.3% | 182 | $14K |
| 81307 | 1.2% | 27 | $12K | |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | <1% | 1,849 | $9K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 3,238 | $9K |
| 81401 | <1% | 1,030 | $7K | |
| 82785 | <1% | 600 | $7K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 298 | $4K |
| 81320 | <1% | 14 | $4K | |
| 87631 | <1% | 132 | $3K | |
| 81400 | <1% | 617 | $3K | |
| 87486 | <1% | 484 | $3K | |
| 81286 | <1% | 308 | $2K | |
| 87581 | <1% | 473 | $2K | |
| 81256 | <1% | 331 | $2K | |
| 80061 | Lipid panel | <1% | 283 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 169 | $2K |
| 81350 | <1% | 68 | $2K | |
| 81344 | <1% | 16 | $2K | |
| 81179 | <1% | 16 | $2K | |
| 87481 | <1% | 773 | $2K | |
| 80053 | Comprehensive metabolic panel | <1% | 284 | $2K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 138 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 247 | $1K |
| 81226 | <1% | 120 | $1K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 253 | $1K |
| 87551 | <1% | 179 | $1K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 216 | $1K |
| 87496 | <1% | 216 | $1K | |
| 87556 | <1% | 180 | $1K | |
| 87500 | <1% | 218 | $996.44 | |
| 87640 | <1% | 244 | $982.17 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 256 | $981.44 |
| 87653 | <1% | 215 | $935.62 | |
| 87641 | <1% | 215 | $907.55 | |
| 87532 | <1% | 181 | $850.94 | |
| 87561 | <1% | 180 | $850.94 | |
| 87541 | <1% | 181 | $850.94 | |
| 87498 | <1% | 181 | $820.53 | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 264 | $796.94 |
| 83540 | <1% | 105 | $532.26 | |
| 82670 | <1% | 74 | $514.05 | |
| 84403 | <1% | 75 | $474.72 | |
| 86225 | <1% | 124 | $467.01 | |
| 86038 | <1% | 125 | $410.98 | |
| 82627 | <1% | 75 | $408.94 | |
| 84270 | <1% | 74 | $399.74 | |
| 84144 | <1% | 72 | $383.64 | |
| 83001 | <1% | 74 | $341.78 | |
| 82533 | <1% | 33 | $339.04 | |
| 84481 | <1% | 32 | $338.75 | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 116 | $337.81 |
| 82607 | <1% | 34 | $313.56 | |
| 86021 | <1% | 29 | $313.04 | |
| 82746 | <1% | 26 | $270.48 | |
| 86200 | <1% | 29 | $269.36 | |
| 86141 | <1% | 34 | $269.36 | |
| 86376 | <1% | 31 | $267.72 | |
| 86803 | <1% | 105 | $252.45 | |
| 82728 | <1% | 31 | $250.70 | |
| 86702 | <1% | 51 | $231.16 | |
| 84466 | <1% | 26 | $224.40 | |
| 83520 | <1% | 59 | $220.96 | |
| 86709 | <1% | 106 | $208.13 | |
| 84146 | <1% | 60 | $201.50 | |
| 87340 | <1% | 107 | $191.02 | |
| 84439 | <1% | 32 | $180.25 | |
| 86696 | <1% | 41 | $179.77 | |
| 86780 | <1% | 77 | $173.31 | |
| 86701 | <1% | 53 | $170.12 | |
| 84702 | <1% | 122 | $168.45 | |
| 86706 | <1% | 21 | $163.21 | |
| 83735 | <1% | 28 | $134.00 | |
| 86695 | <1% | 41 | $122.09 | |
| 86431 | <1% | 58 | $113.25 | |
| 82390 | <1% | 54 | $99.33 | |
| 84550 | <1% | 29 | $93.86 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 14 | $68.45 |
| 85652 | <1% | 26 | $49.68 | |
| 86703 | <1% | 31 | $42.08 | |
| 81355 | <1% | 34 | $38.53 | |
| 86705 | <1% | 82 | $10.59 | |
| 81479 | Unlisted molecular pathology procedure | 0% | 1,485 | $0.00 |
| 81328 | 0% | 94 | $0.00 | |
| 81192 | 0% | 13 | $0.00 | |
| 83002 | 0% | 70 | $0.00 | |
| 81225 | 0% | 25 | $0.00 | |
| 81230 | 0% | 43 | $0.00 | |
| 81231 | 0% | 43 | $0.00 | |
| 81227 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialALSAAB, SAAD (PRESIDENT)
Parent organizationPENTA STATE LLC
| Provider | Location | Paid |
|---|---|---|
| Graham Tomball LLC | Tomball, TX | $386K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.